Date: 2015-04-08
Type of information: Establishment of a new subsidiary in the US
Compound:
Company: Cellectis (France)
Therapeutic area: Cancer - Oncology
Type agreement: establishment of a new subsidiary in the US
Action mechanism:
Disease:
Details: * On April 8, 2015, Cellectis, a gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology using Chimeric Antigen Receptor T-cell therapies (CAR-T) for the treatment of cancer, announced it has established a new subsidiary, Cellectis, Inc. in New York City at the Alexandria Center for Life Science, located on Manhattan’s east side. The U.S. headquarters’ 12,000 square feet includes large state-of-the-art research laboratories. These labs will support the development of its CAR-T pipeline.
Financial terms:
Latest news:
